文献速递抗栓抗凝管理特殊人群用药药物不良反应与药物警戒

慢性抗凝HIV感染者使用长效卡博特韦联合利匹韦林的真实世界病例系列

Long-acting cabotegravir and rilpivirine in people with HIV receiving chronic anticoagulation: A real-world case series.
PubMed 文献 · Br J Clin Pharmacol · 2026-08-18

该研究为西班牙巴塞罗那医院单中心前瞻性观察性队列,纳入2023年2月至2026年4月启动长效卡博特韦联合利匹韦林(LA-CAB+RPV)的964名HIV感染者,其中3人同时接受慢性抗凝治疗。采用标准深部肌内注射并注射后压迫,未观察到临床相关注射部位血肿或出血并发症,所有病例维持病毒抑制。

要点

  • 慢性抗凝并非LA-CAB+RPV的绝对禁忌,但需谨慎选择患者。
  • 标准深部肌内注射联合注射后压迫可降低出血风险。
  • 该系列中3例抗凝患者均维持病毒抑制且无出血并发症。

核心结论

  • 真实世界病例系列提示,仅慢性抗凝治疗本身不应自动排除LA-CAB+RPV的使用。
  • 经仔细选择患者并采用适当注射技术,LA-CAB+RPV可能是接受抗凝治疗的部分HIV感染者的安全有效选择。

研究设计与样本

  • 观察性、前瞻性、单中心队列研究,地点为巴塞罗那医院(Hospital Clínic of Barcelona)。
  • 纳入2023年2月至2026年4月启动LA-CAB+RPV的全部HIV感染者,共964人。
  • 识别随访期间接受慢性抗凝治疗者并评估安全性与病毒学结局。

主要发现

  • 964名启动LA-CAB+RPV的HIV感染者中,3人同时接受慢性抗凝治疗(直接口服抗凝药或低分子量肝素)。
  • 该3人采用标准深部肌内注射技术并注射后压迫,未观察到临床相关注射部位血肿或出血并发症。
  • 所有病例均维持病毒抑制。

临床怎么用

  • 对接受慢性抗凝的HIV感染者,不应仅因抗凝而自动排除LA-CAB+RPV。
  • 使用时应仔细选择患者,并采用标准深部肌内注射与注射后压迫技术。

局限性

  • 仅为单中心病例系列,接受抗凝者仅3例,样本量小。
  • 为观察性研究,缺乏对照组,证据强度有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-acting intramuscular cabotegravir plus rilpivirine (LA-CAB + RPV) is an effective maintenance antiretroviral regimen for virologically suppressed people with HIV. However, its use in individuals receiving chronic anticoagulation is limited by concerns regarding intramuscular bleeding risk, and real-world data are scarce. METHODS: We conducted an observational, prospective, single-centre cohort study including all people with HIV (PVIH) who initiated LA-CAB + RPV at Hospital Clínic of Barcelona since February 2023 until April 2026. Patients receiving chronic anticoagulation during the follow-up were identified and assessed for safety and virological outcomes. RESULTS: Among 964 PVIH who started LA-CAB + RPV in our cohort, three were identified who received concomitantly chronic anticoagulation (direct oral anticoagulants or low-molecular-weight heparin). They received injections using standard deep intramuscular technique with post-injection compression. No clinically relevant injection-site hematomas or haemorrhagic complications were observed. Viral suppression was maintained in all cases. CONCLUSIONS: This real-world case series suggest that chronic anticoagulant therapy alone should not automatically preclude the use of LA-CAB + RPV. With careful patient selection and appropriate injection techniques, LA-CAB + RPV may represent a safe and effective treatment option for selected people with HIV receiving anticoagulation.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Laguno M, Torres B, Martínez-Rebollar M, et al. Long-acting cabotegravir and rilpivirine in people with HIV receiving chronic anticoagulation: A real-world case series. Br J Clin Pharmacol. 2026. PMID: 42613920. doi:10.1002/bcp.70771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。